Extramedullary Relapse in a CML Patient after Allogeneic Stem Cell Transplantation
Myeloid or granulocytic sarcoma (GS) is a tumoral lesion consisting of immature granulocytic cells. It is a rare entity during the course of CML patients especially after allogeneic stem cell transplantation (SCT). Relapse without bone marrow involvement is much rarer. We report a case of CML patien...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2017/6350267 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849410852215586816 |
|---|---|
| author | Asu Fergun Yilmaz Nur Soyer Nazan Ozsan Seckin Cagirgan Ajda Gunes Melda Comert Fahri Sahin Guray Saydam Nur Selvi Gunel Filiz Vural |
| author_facet | Asu Fergun Yilmaz Nur Soyer Nazan Ozsan Seckin Cagirgan Ajda Gunes Melda Comert Fahri Sahin Guray Saydam Nur Selvi Gunel Filiz Vural |
| author_sort | Asu Fergun Yilmaz |
| collection | DOAJ |
| description | Myeloid or granulocytic sarcoma (GS) is a tumoral lesion consisting of immature granulocytic cells. It is a rare entity during the course of CML patients especially after allogeneic stem cell transplantation (SCT). Relapse without bone marrow involvement is much rarer. We report a case of CML patient who relapsed with isolated granulocytic sarcoma after allogeneic SCT during cytogenetic and molecular remission. 28-year-old male was diagnosed as CML and allogeneic SCT was performed because of refractory disease to tyrosine kinase inhibitors. Complete cytogenetic and molecular response was achieved after allogeneic SCT followed by dasatinib treatment. Approximately 5 years after the transplantation, very rapidly progressive lesion was documented and diagnosed as GS although he was at molecular and cytogenetic remission. The patient died during chemotherapy due to sepsis. GS relapse after allogeneic SCT is a very rare type of relapse in CML patients with molecular and cytogenetic remission. Since it is a very aggressive disease with a poor prognosis, combined chemoradiotherapies with other possible options like DLI or second allogeneic SCT should be considered as soon as the diagnosis is confirmed. |
| format | Article |
| id | doaj-art-61365041674e4dd38fa3fcfd57014074 |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-61365041674e4dd38fa3fcfd570140742025-08-20T03:34:57ZengWileyCase Reports in Hematology2090-65602090-65792017-01-01201710.1155/2017/63502676350267Extramedullary Relapse in a CML Patient after Allogeneic Stem Cell TransplantationAsu Fergun Yilmaz0Nur Soyer1Nazan Ozsan2Seckin Cagirgan3Ajda Gunes4Melda Comert5Fahri Sahin6Guray Saydam7Nur Selvi Gunel8Filiz Vural9Hematology Department, Ataturk Training and Research Hospital, İzmir Katip Celebi University Hospital, İzmir, TurkeyHematology Department, Ege University Hospital, İzmir, TurkeyPathology Department, Ege University Hospital, İzmir, TurkeyHematology Department, Medical Park Hospital, İzmir, TurkeyHematology Department, Sivas Numune Hospital, Sivas, TurkeyHematology Department, Inonu University Hospital, Malatya, TurkeyHematology Department, Ege University Hospital, İzmir, TurkeyHematology Department, Ege University Hospital, İzmir, TurkeyMedical Biology Department, Ege University Hospital, İzmir, TurkeyHematology Department, Ege University Hospital, İzmir, TurkeyMyeloid or granulocytic sarcoma (GS) is a tumoral lesion consisting of immature granulocytic cells. It is a rare entity during the course of CML patients especially after allogeneic stem cell transplantation (SCT). Relapse without bone marrow involvement is much rarer. We report a case of CML patient who relapsed with isolated granulocytic sarcoma after allogeneic SCT during cytogenetic and molecular remission. 28-year-old male was diagnosed as CML and allogeneic SCT was performed because of refractory disease to tyrosine kinase inhibitors. Complete cytogenetic and molecular response was achieved after allogeneic SCT followed by dasatinib treatment. Approximately 5 years after the transplantation, very rapidly progressive lesion was documented and diagnosed as GS although he was at molecular and cytogenetic remission. The patient died during chemotherapy due to sepsis. GS relapse after allogeneic SCT is a very rare type of relapse in CML patients with molecular and cytogenetic remission. Since it is a very aggressive disease with a poor prognosis, combined chemoradiotherapies with other possible options like DLI or second allogeneic SCT should be considered as soon as the diagnosis is confirmed.http://dx.doi.org/10.1155/2017/6350267 |
| spellingShingle | Asu Fergun Yilmaz Nur Soyer Nazan Ozsan Seckin Cagirgan Ajda Gunes Melda Comert Fahri Sahin Guray Saydam Nur Selvi Gunel Filiz Vural Extramedullary Relapse in a CML Patient after Allogeneic Stem Cell Transplantation Case Reports in Hematology |
| title | Extramedullary Relapse in a CML Patient after Allogeneic Stem Cell Transplantation |
| title_full | Extramedullary Relapse in a CML Patient after Allogeneic Stem Cell Transplantation |
| title_fullStr | Extramedullary Relapse in a CML Patient after Allogeneic Stem Cell Transplantation |
| title_full_unstemmed | Extramedullary Relapse in a CML Patient after Allogeneic Stem Cell Transplantation |
| title_short | Extramedullary Relapse in a CML Patient after Allogeneic Stem Cell Transplantation |
| title_sort | extramedullary relapse in a cml patient after allogeneic stem cell transplantation |
| url | http://dx.doi.org/10.1155/2017/6350267 |
| work_keys_str_mv | AT asufergunyilmaz extramedullaryrelapseinacmlpatientafterallogeneicstemcelltransplantation AT nursoyer extramedullaryrelapseinacmlpatientafterallogeneicstemcelltransplantation AT nazanozsan extramedullaryrelapseinacmlpatientafterallogeneicstemcelltransplantation AT seckincagirgan extramedullaryrelapseinacmlpatientafterallogeneicstemcelltransplantation AT ajdagunes extramedullaryrelapseinacmlpatientafterallogeneicstemcelltransplantation AT meldacomert extramedullaryrelapseinacmlpatientafterallogeneicstemcelltransplantation AT fahrisahin extramedullaryrelapseinacmlpatientafterallogeneicstemcelltransplantation AT guraysaydam extramedullaryrelapseinacmlpatientafterallogeneicstemcelltransplantation AT nurselvigunel extramedullaryrelapseinacmlpatientafterallogeneicstemcelltransplantation AT filizvural extramedullaryrelapseinacmlpatientafterallogeneicstemcelltransplantation |